Cumulative lifetime risk of ovarian cancer associated with a BRCA1 or BRCA2 mutation is estimated at 44% and 17%, respectively (Kuchenbaecker et al. 2017), with 15.5% of patients with epithelial ovarian cancer found to carry a mutation (Zhang et al. 2011). This evidence concerns the gene BRCA2 and ovarian cancer.